Paolo Tombesi's Net Worth
$3.24 Million
Who is Paolo Tombesi?
Paolo Tombesi has an estimated net worth of $3.24 Million. This is based on reported shares across multiple companies, which include Turning Point Therapeutics, Inc., INSMED Inc, and Epizyme, Inc..
SEC CIK
Paolo Tombesi's CIK is 0001707648
Past Insider Trading and Trends
2020 was Paolo Tombesi's most active year for acquiring shares with 8 total transactions. Paolo Tombesi's most active month to acquire stocks was the month of January. 2020 was Paolo Tombesi's most active year for disposing of shares, totalling 4 transactions. Paolo Tombesi's most active month to dispose stocks was the month of July. 2019 saw Paolo Tombesi paying a total of $0.00 for 280,722 shares, this is the most they've acquired in one year. In 2022 Paolo Tombesi cashed out on 150,761 shares for a total of $2,351,782.02, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Turning Point Therapeutics, Inc. No price found
EVP & Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -29.78K |
$76.00 | -$2,263,128.00 |
0
|
Aug 17
| |||
Form 4
| -3.96% | -1.18K |
$74.94 | -$88,654.02 | 28.7K |
Jul 27
| |||
Form 4
| +119.73% | 16.28K |
—
|
—
| 29.88K |
Feb 9
| |||
Form 4
|
∞
| 13.6K |
—
|
—
| 13.6K |
Jul 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
INSMED Inc (INSM) Snapshot price: $71.04
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 3
| |||
Form 4
|
∞
| 10.67K |
—
|
—
| 10.67K |
Jan 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Epizyme, Inc. No price found
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -1.87% | -1.02K |
$11.21 | -$11,445.41 | 53.47K |
Scheduled
|
Feb 4
| ||
Form 4
| +91.55% | 26.04K |
—
|
—
| 54.49K |
Feb 1
| |||
Form 4
| +22.62% | 4.96K |
$12.55 | -$26,242.05 | 26.91K |
Aug 19 - Aug 20
| |||
Form 4
| +23.64% | 4.2K |
$16.15 | -$29,150.75 | 21.94K |
Scheduled
|
Jun 25 - Jun 26
| ||
Form 4/A
| +29.10% | 4K |
—
|
—
| 17.75K |
Mar 24
| |||
Form 4
| +2.98% | 447 |
$15.28 | -$18,993.04 | 15.44K |
Scheduled
|
Mar 24 - Mar 25
| ||
Form 4
| +353.97% | 11.69K |
—
|
—
| 14.99K |
Feb 3
| |||
Form 4
|
∞
| 3.3K |
$26.72 | -$45,370.56 | 3.3K |
Jan 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||